Experts weigh prospects for Angelman syndrome after Ultragenyx Phase 3 failure
Following the failure of Ultragenyx's experimental therapy in a pivotal trial, specialists say other investigational approaches for the rare neurodevelopmental condition remain active.
A pivotal Phase 3 clinical trial of an experimental drug for Angelman syndrome, a rare neurodevelopmental disorder caused by loss of function of the maternally inherited UBE3A gene, has returned a negative result. The trial was run by Ultragenyx; the result was reported by Stat News on 4 September 2026, following earlier coverage on 3 September 2026 also carried by Stat News.
Angelman syndrome is characterised by severe intellectual disability, absent or minimal speech, seizures, and movement difficulties. It is caused primarily by deletion or mutation of the maternal copy of UBE3A on chromosome 15; the paternal copy is silenced in neurons by genomic imprinting. Therapeutic strategies under investigation aim either to restore UBE3A protein function or to unsilence the paternal allele.
Following the Ultragenyx result, clinical experts quoted by Stat News expressed continued confidence in other experimental approaches in the field, including antisense oligonucleotide programmes and gene-therapy strategies aimed at different mechanistic targets. None of these alternatives has yet reached regulatory approval.
This cluster combines two Stat News items covering the same trial result from different angles; the 3 September item was previously published as a Genetic Current cluster on 2026-09-03. The 4 September item adds expert commentary on the wider therapeutic landscape. Readers should note that both items are behind a STAT+ paywall; full methodological details of the trial are not available from feed-level content.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-09-04After failure of Angelman syndrome drug, experts see hope in other experimental therapies